Japan lists Bharat Biotech’s Covaxin as recognized COVID-19 vaccine
The Indian Embassy in Japan informed the development on Twitter.
COVAXIN
Stay updated with the latest news and articles about COVAXIN.
Latest Articles
US relaxes travel restrictions for Indian tourists, puts India in ‘low-risk’ category
The US Centre for Disease Control and Prevention lifted the travel restrictions and moved India from Level 3 (danger level) to Level 1 (low-risk).
FDA approves Bharat Biotech’s Covaxin for clinical trials in adults in US
Bharat Biotech and its US partner Ocugen said in a statement on Monday that they are committed to bringing Covaxin to the United States and Canada for all age groups.
₹19,675 crore spent till now on procurement of COVID-19 vaccine: GOI
The Union government has set aside an outlay of Rs 35000 crore for the procurement of the COVID-19 vaccine.
USA to allow travellers vaccinated with Covaxin
From November 8, the United States will allow passengers who have been vaccinated with Covaxin to enter the country.
Bharat Biotech’s Covaxin receives approval for emergency use by WHO: Reports
The global health body’s consent will promote more convenient international travel for those who took the Covaxin vaccine, as they would not be obliged to endure the harsh travel restraints inflicted on unvaccinated passengers.
CDSCO extends Covaxin’s shelf-life to 12 months from the date of manufacturing
The announcement comes just in time as the World Health Organisation has reportedly approved Bharat Biotech’s Covaxin for its Emergency Use Listing.
Cannot play with lives of people by ordering revaccination with Covishield without any data: SC
The top court was trying a petition that said that Covaxin was not recognised by the World Health Organisation (WHO). People here are encountering challenges in obtaining approval to travel overseas.
Covaxin approval delayed as WHO asks for additional data from Bharat Biotech
The TAG will now reconvene on November 3 for the final EUL assessment if the data asked of Bharat Biotech is provided by them soon.
Bharat Biotech’s Covaxin gets approval for emergency use for children aged 2-18 years
Two doses of Covaxin are expected to be distributed to children with a gap of 28 days. The government has set an interval of 4-6 weeks for adults between the two shots.
Brazil discards Covaxin’s application for emergency use
After the termination of MoU by Bharat Biotech, the Brazilian regulatory agency had announced its suspension of Phase 3 trials of Covaxin.
AIIMS chief explains the need of COVID vaccine booster shots
Dr. Randeep Guleria stated, as mutations of the coronavirus emerge, the beneficiaries who have been vaccinated may still need a booster with a second-generation COVID 19 shot.
AIIMS Delhi: second dose trial of Covaxin on 2-6 years old children to take place
AIIMS in New Delhi will commence the second dose trial of Bharat Biotech's COVID-19 vaccine, Covaxin, for children aged 2-6 years.
WHO chief scientist: Decision on Covaxin approval to be taken in 4-6 weeks
The emergency use listing (EUL) status of Covaxin will be decided in the next four to six weeks by WHO.
Chief Scientist of WHO said Covaxin’s data looks good
She said that WHO would not recommend any booster shots anytime soon and the focus would remain on widening the scopes of primary vaccinations.
Showing 15 of 45 articles